

Detection of Toxicity to Reproduction for Human Pharmaceuticals Paving the Way for Alternative Assays in the 3rd Revision of ICH S5

1st EMA Workshop on Non-Animal Approaches, Oct 5th 2017

Günter Waxenecker

Austrian Agency for Health and Food Safety

Disclaimer

- ICH: "The views and opinions expressed in the following presentation are the personal views of the author and do not necessarily represent the views of the ICH or other members of the EWG."
- EMA: "The views expressed in this presentation are my personal views and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties."
- BASG/AGES: "The views expressed in this presentation are my personal views and may not be understood or quoted as being made on behalf of or reflecting the position of the Austrian Competent Authority."



Outline

Introduction

Alternative assays in reprotox testing?

3rd Revision of ICH S5

Conclusions

Introduction Two species EFD testing since Thalidomide





https://commons.wikimedia.org/wiki/File%3A NCP14053.jpg

https://commons.wikimedia.org/wiki/File%3AA rtificial_limbs_for_a_thalidomide_child%2C_196 1-1965._(9660575567).jpg



Fuzura 1. Gross Delarmities in a Newborn Infant (A) (Reproduced from Pfeiffer and Kosenow' with the Permission of the Publisher) and in a Newborn Rabbit (B) after Maternal Ingestion of Thalidomide in Pregnancy.

Thalidomide Embryopathy in Hybrid Rabbits Theodore H. Ingalls, M.D.[†], Francis J. Curley[‡], and Peter Zappasodi[§] N Engl J Med 1964; 271:441-444

Rat & rabbit testing became gold standard for EFD studies
 Single case driven? *Two proper species*

Introduction Unique Aspects of Reproductive Toxicity



• EFDT studies in rat/rabbit have added value over single studies see Theunissen et al. 2016

<u>Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic</u> <u>dose and developmental effects</u>

Critical Reviews in Toxicology , 2016

<u>Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the</u> <u>nature and severity of developmental effects</u>

Critical Reviews in Toxicology , 2016

- The second secon
- Maternal toxicity/exaggerated pharmacology complicate data interpretation of *in vivo* studies
- Data on human teratogenicity are scarce
 - If the aim is to replace rat/rabbit EFD testing the alternative assays need to predict rat/rabbit teratogenicity/fetal lethality
- 3R considerations:
 - Segment I-III studies, incl DRF studies: 6792 total animal use Chapman et al. 2013

Assay	Developmental period	Test accuracy %	Animal use	Limitations	ECVAM validation	Lit.
Rat/rabbit whole embryo culture	Early to mid organogenesis (Itd period of embryogenesis)	80% for 20 tested cmpds	Yes	No metab., (experimental <i>ex</i> <i>vivo</i> approaches) -interlab variation(subjecti vity), -costly, time consuming	Yes (Rat)	Piersma et al. 2004
Zebrafish	cleavage, segmentation, majority of organogenesis to skeletogenesis	31 test compounds; 87%, 75-92%	Yes (non- mammali an)	Nonmammalian metabolisation, Chorion may hamper compound uptake (DMSO)	No (Zebrafish embryo acute toxicity test for acute aquatic toxicity testing, 2014)	Brannen 2010 Van den Bulck 2011
Embryonic stem cell test "Hanging drop"	Cardiomyocyte differentiation	78% 81%	No	Metab., less predictive for drugs (ReProTect)	Yes	Genschow 2002 Whitlow 2007 Genschow 2004 Marx-Stölting 2009
Micromass assay (limb bud)	Chondrocyte differentiation	70%	Yes	No metabolic competence	Yes	Genschow 2002 Spielmann 2004



General Features and Performance

• Alternative tests are

reductionistic, show poor specificity (true negative rate) highly sensitive: highly predictive for positive results



Validation efforts failed (by ECVAM, ICCVAM,...)
 challenge of regulatory acceptance



SI Health and Environmenta

Current Step 4 version Parent Guideline dated 24 June 1993 (Addendum dated 9 November 2000 incorporated in November 2005) Alternative assays in reprotox testing? Use of Alternative Assays




ICH S5(R2) already highlights the value of "other test systems" also states that *"other test systems cannot provide assurance of the absence of effect nor provide perspective in respect of risk/exposure*".

- Nonetheless, after two decades of scientific progress, a number of in-vitro, ex-vivo and non-mammalian in-vivo assays are being used as discovery screens for EFD.
- In addition, some of these assays are being examined for **use for regulatory purposes under defined scenarios**.

Concept paper ICH S5(R3)

@ *in-vitro, ex-vivo* or non-mammalian *in-vivo* assay(s) intended to evaluate a developmental endpoint = alternative assay(s)




Use of Alternative Assays




Alternative assays should be **GLP** compliant and **qualified** for its intended **context of use** (e.g.):

- As part of an integrated testing strategy (ITS) for EFD endpoints (Scenarios)
- Deferral of definitive studies
- Complete replacement of one species when used in conjunction with an EFD study in limited circumstances
- Contributing to the weight of evidence in case of equivocal animal data
- Toxicity precludes attaining a relevant exposure
- Low systemic exposure in humans (ophthalmics)

Context of use: applies to regulatory conditions under which the results of an assay can be relied upon.





3rd Revision of ICH S5 Rules of the Exemplified Testing Scenarios



Scenarios applicable when there are at least 2 relevant mammalian species (crf. Species selection)

IF a qualified alternative test plus a negative definitive EFD study in another species are NEGATIVE – label negative

IF a single preliminary or definitive EFD study at clinically relevant exposures is POSITIVE – no further animal testing

IF an alternative test is POSITIVE, it may be over-ruled if a definitive EFD study in a rodent and non-rodent is NEGATIVE

3rd Revision of ICH S5 **Proposed Basic Principles for Possible Regulatory Acceptance**

Qualification of Alternative Test Systems for Regulatory Acceptance

Provides a framework including ICH Reference Compound List (RCL): EFD data, organized by overarching categories

RCL is intended to be periodically updated.

This list is generated recognizing that the <u>context of use</u> will inform on acceptability of particular alternative assessments.

Category	Positive Controls	Negative Controls
	Sotalol	Hydrochlorothiazide
	Almokalant	Chlorthalidone
	Diltiazem	
Channel Modulator	Topiramate	
	Trimethadione	
	Phenytoin (Diphenylhydantoin)	
	Carbamazepine	
	Cyclophosphamide	
	Busulfan	
DNA Modifiers	Cisplatin	
	Thiotepa	
	Aspirin	
	Captopril	Saxagliptin
Enzyme Modulator	Enalapril	Vildagliptin
	Methimazole (Thiamazole)	· · · · · · · · · · · · · · · · · · ·
	Dexamethasone	Progesterone
Hormone/Steroid	Fluticasone	Besterone
	Afatinib	
	Ceritinib	
	Dabrafenib	
	Dasatinib	
Kinase Modulator	Ibrutinib	
initiase informator	ibiutino	
	Pazopanib	
	Tacrolimus	
	Imatinib	
	Cytarabine	
	5-Fluorouracil	
	Hydroxyurea	
Nucleoside Modulator/	Methotrexate	
Central metabolite inhibitor	Methoticxate	
Central metabolite initiotor	Ribavirin	
	Teriflunomide	
	Warfarin	
		Amoviaillin
	Artesunate / amodiaquine	Amoxicillin
	Clarithromycin	Clindamycin
	Doxycycline	Cyclobenzaprine
	Fluconazole	Erythromycin
Other	Pomalidomide	Sulfasalazine
	Tafamidis	
	Telavancin	
	Thalidomide	
	Valproic acid	
		Cetirizine
	Bosentan	Cyproheptadine
Receptor Modulator	Clobazam	Doxylamine
Acceptor mountain	Fingolimod	Maraviroc
	Plerixafor	Metoclopramide
	Sumatriptan	Nizatidine
Second Messenger Modulator	Theophylline	
	Acitretin	
Transcription Modulator	Isotretinoin (13-cis-retinoic acid)	
	Vismodegib	



-compounds known for their TEFL (teratogenic and/or embryofetal lethal) effects in animals or humans -from different chemical/pharmacologic classes -with overlap with both negative and positive compounds (coverage of diverse chemical structures and mode of action)



Proposed Selection factors for ICH List of Reference Compounds ctd.

- Availability of PK and TK data in the test species
- Pharmaceuticals are preferred, chemicals considered, no biotech cmpds
- Favours compounds with direct effects on the fetus, a few depending on metabolic activation, cytotoxic/genotoxic cmpds to a limited extent
- Negative cmpds included to assess assay specificity: should be negative at all doses, or positive at high exposures (provided transition predicted)
- Evaluate performance to detect species-specific differences; Commercial availability;...

3rd Revision of ICH S5 Proposed Performance Factors



- At least 45 compounds in total: substitution of RCL cmpds with other compounds possible, but their use should be justified
- Multiple classes (at least 2 or 3 from each class)
- An approx. ratio 2:1 of positive to negative cmpds to ensure selectivity
- Sensitivity to detect a positive signal in an assay should be at least 80%, with evidence of selectivity
- Evaluation should identify applicability domain and any limitations of the assay(s), include assessments of accuracy, and reproducibility over time
 physical properties or specific
- Inter-lab reproducibility and transferability
- Individual assays or combinations

physical properties or specific types of substances for which the assay is appropriate. ...**applicable chemical space**.

AGES

Proposed Assay Qualification Information to be Provided to Health Authorities

Detailed description of the predictive model:

what species trying to predict, what reproductive endpoint it assesses.

Details of the algorithm for determining pos and neg outcomes correlate concentrations to *in vivo* exposure (exposure-based risk assessment)

Training Set: nmt 15% compounds from the RCL

Performance of Training and **Test Set**: *sensitivity, specificity, positive predictive value, and negative predictive value*;

Define the category of compounds that can and cannot be predicted **Human teratogens** not detected *in vivo* by rat/rabbit: present data separately

AG Proposed Assay Qualification Information to be Provided to Health Authorities ctd.

- Assay reproducibility: at least one pos ctrl and one neg ctrl in each run or interspersed over time bw test compound runs
- Periodic reassessment of several compounds from the RCL
- Source of reagents, biologic materials, cmpds tested
- Source/reference of all *in vivo* exposure data used for compounds in the qualification data set (except for those in the RCL)
- Expectation that regulatory studies should generally be conducted in compliance with **GLP**
- State if the alternative assay has been **previously submitted to any** health authority



Proposed Qualification of Alternative Test Systems for Regulatory Acceptance - Summarized

Assays qualified based on performance (reliability and predictivity) with known developmental toxicants

The ICH Reference Compound List is not complete.

- We are <u>soliciting data for additional reference compounds</u> for potential inclusion into the list, including relevant information.
- Template with examples is provided.
- No centralized approval process for regulatory acceptance of qualified alternative assays is proposed – remains agency specific.

3rd Revision of ICH S5 Summary of Proposed Guidance Revision



Focus on application of human risk assessment

- Additional dose selection endpoints
- Emphasizes the use of existing data
- Integrated testing strategies for assessing reproductive toxicity, including for biologics
- Guidance on alternative assays: requirement of use & possible integration in risk assessment
- Focus of EFD risk assessment on teratogenicity or embryo/fetal lethality



Questions?



http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html